Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Papers of the Week
Annotation


Wilcock DM, Lewis MR, Van Nostrand WE, Davis J, Previti ML, Gharkholonarehe N, Vitek MP, Colton CA. Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. J Neurosci. 2008 Feb 13;28(7):1537-45. PubMed Abstract

  
Comments on Paper and Primary News
  Comment by:  Karen Duff, ARF Advisor, Emmanuel PLANEL
Submitted 28 February 2008  |  Permalink Posted 28 February 2008

The article by Wilcock et al. describes tauopathy development in a transgenic APP mouse lacking NOS. NO is known as a peripheral and central mediator in temperature regulation (Simon, 1998). In addition, there is extensive literature showing that NOS knockout mice have problems regulating body temperature, and are prone to hypothermia in stress situations (Koedel et al., 2001; Spanagel et al., 2002; Saia and Carnio, 2006; Saia et al., 2008). Hypothermia induces tau hyperphosphorylation both in vivo and in vitro (Planel et al., 2004). This phenomenon is extremely sensitive to body temperature (+80 percent per degree C drop), and a decrease of 1-3 degrees C will induce a 200-300 percent increase in tau phosphorylation (Planel et al., 2007). Moreover, transgenic APP mice are also prone to hypothermia (Huitron-Resendiz et al., 2002; Iivonen et al., 2003). It is therefore possible that the increase in phospho-tau shown in the APP/NOS-/- mice reflects that the NOS-/- derived mice have deficits in thermoregulation, which might be exacerbated by stress imposed by elevated Aβ levels....  Read more

  Comment by:  Carol Colton, William Van Nostrand, Michael Vitek, Donna M. Wilcock
Submitted 12 March 2008  |  Permalink Posted 13 March 2008

Reply by CA Colton, DM Wilcock, J Oddo, WE Van Nostrand, MP Vitek, and D Christensen
We would like to thank Drs. Duff and Planel for their comments on our mouse model of AD. We believe, however, that the tau pathology we observed in the old mice is not due to hypothermia. As shown in Table 1, the core body temperatures of APPSwDI and of APPSwDI/NOS2-/- mice at 52-60 weeks of age are not significantly different. The only difference between APPSwDI and APPSwDI/NOS-/- mice is the deletion of a functional NOS2 gene. When combined with deposition of β amyloid, this NOS2 deletion is associated with a significantly increased level of AT8-positive immunoreactivity in APPswDI/NOS2-/- mice when compared to the APPSwDI mice (Colton et al., 2007, Wilcock et al., 2008).
Genotype 	               Core body temperature (oC)
APPSwDI 	               35.69 + 0.13 (n = 14)
APPSwDI/NOS2-/-                35.61 + 0.13 (n = 7)
Table 1: Core body temperature: Core body temperature was measured at 10 a.m. using a soft tip, small diameter YSI temperature probe inserted 1...  Read more
  Submit a Comment on this Paper
Cast your vote and/or make a comment on this paper. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend this paper

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
 
 

REAGENTS/MATERIAL:
Antibodies used in this study are:
For immunohistochemistry, mouse monoclonal anti-NeuN (A60) (Chemicon); rabbit anti-Neuropeptide Y (Chemicom); mouse monoclonal anti-PHF Tau, phospho Ser202 (AT8) (Pierce Endogen); mouse monoclonal anti-total Tau (Tau-5) (Calbiochem); rabbit anti-cleaved Caspase-3 (Cell Signaling); rat monoclonal anti-CD45 (AbD Serotec).
For immunofluorescence, rabbit anti-neuron-specific β-tubulin (Abcam); rabbit anti-Aβ N terminal (Biosource).
For Western Blotting, mouse monoclonal anti-PHF Tau, phospho Ser202 (AT8) (Pierce Endogen); mouse monoclonal anti-GAPDH (6C5) (Advanced ImmunoChemical).

Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad